HomeNewsBusinessIndiGo aims to grow north of mid-teens this FY, says CEO Pieter Elbers

IndiGo aims to grow north of mid-teens this FY, says CEO Pieter Elbers

IndiGo is seeing robust demand for flying in current quarter and yield in the current quarter were higher when compared on year to a capacity constraints in the domestic Indian market.

May 19, 2023 / 07:42 IST
Story continues below Advertisement
Pieter Elbers
IndiGo plans to focus on reliability, competitive prices, and punctuality on our international operations to grow, said CEO Pieter Elbers

IndiGo will aim to grow its revenues and bottom line in the high teens when compared on year in 2023-24, the airline's Chief Executive Officer Pieter Elbers said on May 18, as India's biggest airline reported a profit of Rs 919 crore in the March quarter.

Speaking in a post-earnings conference call, Elbers said IndiGo is seeing robust demand for flying in current quarter and yield is higher when compared to the year-ago period that saw capacity constraints in the domestic market.

Story continues below Advertisement

"Due to the grounding of a competitor there is limited capacity in the domestic market at the moment," Elbers said.

He added that it would be very premature to comment on acquisition of any aircraft that may be available domestically in India, due to a competitor being grounded.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show